TY  - GEN
AU  - Strangfeld,A
AU  - Richter,A
AU  - Siegmund,B
AU  - Herzer,P
AU  - Rockwitz,K
AU  - Demary,W
AU  - Aringer,M
AU  - Meißner,Y
AU  - Zink,A
AU  - Listing,J
TI  - Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
SN  - 1468-2060
PY  - 2017///0613
KW  - Abatacept
KW  - therapeutic use
KW  - Abdomen, Acute
KW  - epidemiology
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Antirheumatic Agents
KW  - Arthritis, Rheumatoid
KW  - blood
KW  - Biological Products
KW  - C-Reactive Protein
KW  - metabolism
KW  - Germany
KW  - Humans
KW  - Incidence
KW  - Intestinal Perforation
KW  - Middle Aged
KW  - Prospective Studies
KW  - Registries
KW  - Risk Assessment
KW  - Rituximab
KW  - Sigmoid Diseases
KW  - Single-Blind Method
KW  - Tumor Necrosis Factor-alpha
KW  - antagonists & inhibitors
N1  - Publication Type: Comparative Study; Journal Article; Observational Study
UR  - https://doi.org/10.1136/annrheumdis-2016-209773
ER  -